

Ir-Na Cooperativity Controls the Diastereoselectivity of Borrowing Hydrogen C-C Alkylation on Isosorbide: Synthesis Methodology and Mechanistic Investigation

Jordan François,^a Jordan Rio,^a Erwann Jeanneau,^b Marie-Ève L. Perrin,^a Maïwenn Jacolot,^{a*} Pierre-Adrien Payard,^{a*} Florence Popowycz^{a*}

^aUniversité de Lyon, INSA Lyon, Université Lyon 1, CNRS, CPE Lyon, UMR 5246, ICBMS, 1 rue Victor Grignard, 69621, Villeurbanne Cedex, France.

Supplementary Information

Table of contents

General Note.....	5
General procedure for the borrowing hydrogen reaction	5
Preparation of catalysts.....	5
[Cp*-Ir-NTr · HCl] (Ir-1):.....	5
[Cp*Ir(Ts*-dpen)(<i>R,R</i>)] (Ir-2).....	6
Substrates.....	7
(3 <i>R</i> ,6 <i>S</i>)-6-(Benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (1)	7
(3 <i>R</i> ,6 <i>R</i>)-6-((<i>Tert</i> -butyldimethylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (6)	7
(3 <i>R</i> ,6 <i>S</i>)-6-Hydroxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate	7
(3 <i>R</i> ,6 <i>S</i>)-6-((<i>Tert</i> -Butyldiphenylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate.....	8
(3 <i>R</i> ,6 <i>S</i>)-6-((<i>Tert</i> -butyldiphenylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (7).....	8
(3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate	9
(3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-ol (8).....	9
(3 <i>R</i> ,6 <i>S</i>)-6-(<i>Tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (9)	10
5-Methyltetrahydrofuran-3-ol.....	10
(3 <i>R</i> ,4 <i>S</i>)-4-Methyltetrahydrofuran-3-ol (±)	11
(3 <i>R</i> ,4 <i>S</i>)-4-Propyltetrahydrofuran-3-ol (±)	11
(3 <i>S</i> ,4 <i>S</i>)-4-Methoxytetrahydrofuran-3-ol (±)	11
(3 <i>R</i>)-Hexahydrofuro[3,2- <i>b</i>]furan-3-ol	12
Blank reactions:	13
Products obtained from BH	14
2-((3 <i>R</i> ,6 <i>S</i>)-6-(Benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2)	14
2-((3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (10).....	14
2-((3 <i>R</i> ,6 <i>S</i>)-6-(<i>Tert</i> -Butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12)	15
1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13)	15
1-(2,3,4,5,6-Pentamethylphenyl)-2-(4-Propyltetrahydrofuran-3-yl)ethanone (16)	17
2-((3 <i>R</i> ,4 <i>R</i>)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17).....	17
2-((3 <i>R</i>)-Hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18).....	18
1-(2,3,4,5,6-Pentamethylphenyl)-2-(3 <i>a</i> ,5,6,6 <i>a</i> -Tetrahydrofuro[3,2- <i>b</i>]furan-3-yl)ethanone (18')..	18
References:	19
Computational Modelling:.....	20
Computational details:	20
Speciation of [Ir ^{III}] complex and substrates:.....	20
Alternative mechanisms:	21

Interaction-distortion analyses:.....	23
Cartesian coordinates:.....	24
References:	24
Spectral data:	26
¹ H NMR spectrum of [Cp*-Ir-NTr · HCl] (Ir-1) (300 MHz, CDCl ₃).....	26
¹ H NMR spectrum of <i>N</i> -((1 <i>R</i> ,2 <i>R</i>)-2-amino-1,2-diphenylethyl)-2,3,4,5,6-pentamethylbenzenesulfonamide (300 MHz, CDCl ₃)	27
¹ H NMR spectrum of [Cp*Ir(Ts*-dpen)(<i>R,R</i>)] (Ir-2) (300 MHz, CDCl ₃).....	27
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-(benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (1) (300 MHz, CDCl ₃)	28
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-hydroxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate (400 MHz, CDCl ₃)	30
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-((<i>tert</i> -butyldiphenylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate (400 MHz, CDCl ₃).....	31
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-((<i>tert</i> -butyldiphenylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (7) (400 MHz, CDCl ₃).....	32
¹³ C NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-((<i>tert</i> -butyldiphenylsilyl)oxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (7) (101 MHz, CDCl ₃).....	32
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl acetate (400 MHz, CDCl ₃)	33
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-ol (8) (400 MHz, CDCl ₃)	34
¹³ C NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-ol (8) (101 MHz, CDCl ₃)	34
¹ H NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-(<i>tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (9) (400 MHz, CDCl ₃)	35
¹³ C NMR spectrum of (3 <i>R</i> ,6 <i>S</i>)-6-(<i>tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-ol (9) (101 MHz, CDCl ₃)	35
¹ H NMR spectrum of (3 <i>R</i> ,4 <i>S</i>)-4-methyltetrahydrofuran-3-ol (±) (400 MHz, CDCl ₃)	37
¹³ C NMR spectrum of (3 <i>R</i> ,4 <i>S</i>)-4-methyltetrahydrofuran-3-ol (±) (101 MHz, CDCl ₃)	37
¹ H NMR spectrum of (3 <i>R</i> ,4 <i>S</i>)-4-propyltetrahydrofuran-3-ol (±) (300 MHz, CDCl ₃).....	38
¹³ C NMR spectrum of (3 <i>R</i> ,4 <i>S</i>)-4-propyltetrahydrofuran-3-ol (±) (75 MHz, CDCl ₃).....	38
¹ H NMR spectrum of (3 <i>S</i> ,4 <i>S</i>)-4-methoxytetrahydrofuran-3-ol (±) (400 MHz, CDCl ₃).....	39
¹³ C NMR spectrum of (3 <i>S</i> ,4 <i>S</i>)-4-methoxytetrahydrofuran-3-ol (±) (101 MHz, CDCl ₃).....	39
¹ H NMR spectrum of (3 <i>R</i>)-hexahydrofuro[3,2- <i>b</i>]furan-3-ol (300 MHz, CDCl ₃)	40
¹³ C NMR spectrum of (3 <i>R</i>)-hexahydrofuro[3,2- <i>b</i>]furan-3-ol (75 MHz, CDCl ₃)	40
¹ H NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-(benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) (400 MHz, CDCl ₃).....	41
¹³ C NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-(benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) (101 MHz, CDCl ₃).....	41

2-((3 <i>R</i> ,6 <i>S</i>)-6-(Benzyloxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) – S73	42
¹ H NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (10) (400 MHz, CDCl ₃).....	43
¹³ C NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-Methoxyhexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (10) (101 MHz, CDCl ₃).....	43
¹ H NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-(<i>tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12) (400 MHz, CDCl ₃).....	44
¹³ C NMR spectrum of 2-((3 <i>R</i> ,6 <i>S</i>)-6-(<i>tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12) (101 MHz, CDCl ₃).....	44
¹ H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13) (400 MHz, CDCl ₃)	45
¹³ C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13) (101 MHz, CDCl ₃).....	45
¹ H NMR spectrum of 2-(5-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (14) (400 MHz, CDCl ₃)	46
¹³ C NMR spectrum of 2-(5-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (14) (101 MHz, CDCl ₃)	46
¹ H NMR spectrum of 2-(4-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (15) (400 MHz, CDCl ₃)	47
¹³ C NMR spectrum of 2-(4-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (15) (101 MHz, CDCl ₃)	47
¹ H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethanone (16) (400 MHz, CDCl ₃)	48
¹³ C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethanone (16) (101 MHz, CDCl ₃)	48
¹ H NMR spectrum of 2-((3 <i>R</i> ,4 <i>R</i>)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17) (400 MHz, CDCl ₃).....	49
¹³ C NMR spectrum of 2-((3 <i>R</i> ,4 <i>R</i>)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17) (101 MHz, CDCl ₃).....	49
¹ H NMR spectrum of 2-((3 <i>R</i>)-hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18) (400 MHz, CDCl ₃).....	50
¹³ C NMR spectrum of 2-((3 <i>R</i>)-hexahydrofuro[3,2- <i>b</i>]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18) (101 MHz, CDCl ₃).....	50
¹ H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(3 <i>a</i> ,5,6,6 <i>a</i> -Tetrahydrofuro[3,2- <i>b</i>]furan-3-yl)ethanone (18') (400 MHz, CDCl ₃).....	51
¹³ C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(3 <i>a</i> ,5,6,6 <i>a</i> -Tetrahydrofuro[3,2- <i>b</i>]furan-3-yl)ethanone (18') (101 MHz, CDCl ₃).....	51

General Note


Reagents and solvents were supplied by Aldrich, TCI, or Alfa Aesar and purchased at the highest commercial quality to be used without further purification. NMR spectra were recorded on a Bruker 300 (^1H : 300 MHz; ^{13}C : 75 MHz) or Bruker 400 (^1H : 400 MHz; ^{13}C : 100 MHz) spectrometers at 298 K, using CDCl_3 as solvent. The chemical shifts (δ , ppm) are referenced to the residual solvent peak and coupling constants (J) are reported in the standard fashion. The residual peak of CHCl_3 was set at 7.26 ppm for ^1H NMR and the central peak of CDCl_3 was set at 77.16 ppm for ^{13}C NMR. The following abbreviations are used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. NMR peak assignments were performed for each compound using classical 1D and 2D NMR (COSY, HSQC, HMBC). For better clarity, a mean of close measured coupling constants for correlated protons are displayed in NMR assignments. Electrospray ionization (ESI) mass spectrometry (MS) experiments were performed on a Thermo Finnigan LCQ Advantage mass spectrometer. Infrared (IR) spectra were recorded with an IRAffinity-1 Shimadzu spectrometer using attenuated total reflectance (ATR Miracle 10), and the wave-numbers were expressed in cm^{-1} . Optical rotations were measured with a Perkin–Elmer 241 polarimeter with a 5 cm cell (concentration c expressed in g/100 mL). High-resolution mass spectra (HRMS) were recorded on a Finnigan Mat 95xL mass spectrometer using either the electrospray (ESI) or atmospheric pressure chemical ionization (APCI) technique. Analytical thin-layer chromatography was carried out on silica gel Merck 60 D254 (0.25 mm). Flash chromatography was performed on Merck Si 60 silica gel (40–63 μm).

General procedure for the borrowing hydrogen reaction

To a 10 mL Biotage[®] microwave vial equipped with a stirrer bar were introduced mono-protected isosorbide (1.0 eq.), pentamethylacetophenone (1.1 eq.), base (2.0 eq.), catalyst (5 mol %) and 1,3,5-trimethoxybenzene as standard in the open vessel. The vial was placed under inert atmosphere by performing 3 cycles vacuum / N_2 . Then, toluene [1.0 M] was introduced and the vial was sealed with a microwave vial cap. The vial was heated at 120 $^\circ\text{C}$ for 24 h in a preheated tray. The mixture was cooled down to room temperature and few drops of water (100 μL) were added. The reaction vessel was washed with DCM (10 mL) and concentrated under reduced pressure. Purification by flash column chromatography packed with silica afforded the title compound.


Preparation of catalysts

[Cp*-Ir-NTr·HCl] (Ir-1):




NaOAc (55 mg, 0.67 mmol, 2.7 eq.) was added to a mixture of $[\text{Cp}^*\text{IrCl}_2]_2$ (200 mg, 0.25 mmol, 1.0 eq.) and TrNH_2 (144 mg, 0.56 mmol, 2.2 eq.) in DCM (10 mL). After stirring at r.t. for 20 h, the solution was concentrated. The crude mixture was diluted with toluene (50 mL) and filtered off on a celite[®] pad and washed with toluene (50 mL). Evaporation of the filtrate to dryness afforded the iridacycle $[\text{Cp}^*\text{Ir-NTrHCl}]$ product as a yellow to orange powder (335 mg, quant.). ^1H NMR (300 MHz, CDCl_3) δ 1.41 (s, 15H, $\text{C}(\text{CH}_3)_5$), 7.03–7.40 (m, 14H, CH_{Ph}). NMR spectrum was consistent with the literature.^[1]

***N*-((*1R,2R*)-2-Amino-1,2-diphenylethyl)-2,3,4,5,6-pentamethylbenzenesulfonamide**



To a solution of (*R, R*)-1, 2-diphenylethylenediamine (750 mg, 3.53 mmol, 1.0 eq.) in anhydrous DCM (40 mL) under an argon atmosphere at 0 °C was introduced triethylamine (540 μ L, 3.89 mmol, 1.1 eq.). After stirring for 20 min., pentamethylbenzenesulfonyl chloride (960 mg, 1.1 mmol) in anhydrous DCM (5 mL) was added dropwise to the reaction mixture at 0 °C. The solution was allowed to stir at r.t. for 18 h. After complete conversion, water (30 mL) was added and the aqueous phase was extracted with DCM (4 x 20 mL). The organic layers were combined, dried over Na₂SO₄ and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography (SiO₂, pentane/EtOAc, 1/1) to afford the title compound as a white solid (1.19 g, 79%). ¹H NMR (300 MHz, CDCl₃) δ 2.07 (s, 6H, 2 CH₃), 2.12 (s, 3H, CH₃), 2.36 (s, 6H, 2 CH₃), 4.36 (bs, 1H), 5.95 (bs, 1H), 6.86–7.13 (m, 10H, 10 CH_{Ph}). NMR spectrum was consistent with the literature.^[2]


[Cp*Ir(Ts*-dpen)(*R,R*)] (Ir-2)



A mixture of *N*-((*1R,2R*)-2-amino-1,2-diphenylethyl)-2,3,4,5,6-pentamethylbenzenesulfonamide (200 mg, 0.50 mmol, 1.0 eq.), [Cp*IrCl₂]₂ (200 mg, 0.25 mmol, 0.5 eq.) and KOH (140 mg, 2.5 mmol, 5 eq.) in DCM (6 ml) and water (6 ml) was stirred for 30 minutes under Ar atmosphere at r.t.. The aqueous phase was extracted with DCM (3 x 10 mL) and the organic phases were dried over Na₂SO₄. The purple organic layer was filtered off on a Celite[®] pad and washed with Et₂O (20 mL). The filtrate was concentrated under reduced pressure to afford the desired product [Cp*Ir(Ts*-dpen)(*R,R*)] as a dark purple powder (363 mg, 97%). ¹H NMR (300 MHz, CDCl₃) δ 1.96 (s, 6H, 2 CH₃), 1.97 (s, 6H, 2 CH₃), 2.03 (s, 15H, C(CH₃)₅), 2.13 (s, 3H, CH₃), 3.92 (s, 1H), 3.96 (s, 1H), 5.14 (bs, 1H, NH), 7.08–7.41 (m, 10H, 10 CH_{Ph}). NMR spectrum was consistent with the literature.^[2]


Substrates

(3*R*,6*S*)-6-(Benzyloxy)hexahydrofuro[3,2-*b*]furan-3-ol (1)




To a solution of isosorbide (5.0 g, 34.2 mmol, 1.0 eq.) in distilled water (15 mL) was introduced a 50%wt/H₂O solution of CsOH (5.96 mL, 34.2 mmol, 1.0 eq.) and benzyl chloride (3.94 mL, 34.2 mmol, 1.0 eq.). The biphasic solution was stirred at 80°C for 22 h. The reaction was quenched with HCl (2N) until neutral pH. Then, the water phase was extracted with EtOAc (3 x 30 mL). The organic layers were combined and dried over Na₂SO₄, filtered and concentrated under reduced pressure. The resulting yellow solid was washed with cold Et₂O (100 mL) and gave the title compound **1** as a white solid (1.52 g, 20%). ¹H NMR (400 MHz, CDCl₃) δ 2.65 (d, *J* = 7.2, 1H, OH), 3.56 (dd, *J* = 9.5, 5.7, 1H, H₂), 3.82–3.92 (m, 2H, H₂, H₅), 4.05–4.16 (m, 2H, H₆, H₅), 4.25–4.33 (m, 1H, H₃), 4.53 (app dt, *J* = 4.8, 1.0, 1H, H_{6a}), 4.55 (d, *J* = 12.0, 1H, CH₂Ph), 4.61 (d, *J* = 12.0, 1H, CH₂Ph), 4.65 (app t, *J* = 4.8, 1H, H_{3a}), 7.30–7.38 (m, 5H, H_{Ph}). ¹³C NMR (101 MHz, CDCl₃) δ 71.7 (CH₂Ph), 72.4 (C₃), 73.5 (C₅), 73.8 (C₂), 81.9 (C_{3a}), 83.6 (C₆), 86.1 (C_{6a}), 127.9 (2 CH_{Ph}), 128.1 (C_{Ph}), 128.7 (2 CH_{Ph}), 137.6 (C_{qPh}). MS (ESI/BS) [M + Na]⁺: calcd. for C₁₃H₁₆O₄Na: 259.1, found 259.1, [2M + Na]⁺: calcd. for C₂₆H₃₂O₈Na₂: 495.1, found 495.1. NMR spectra were consistent with the literature.^[3]

(3*R*,6*R*)-6-((*Tert*-butyldimethylsilyloxy)hexahydrofuro[3,2-*b*]furan-3-ol (6)



To a solution of isomannide (3.01 g, 20.60 mmol, 1 eq) in DMF (22.5 mL), TBDMSCl (3.40 g, 22.56 mmol, 1.1 eq) then imidazole (3.37 g, 45.40 mmol, 2.4 eq) were added. The reaction was stirred at r.t. under an argon atmosphere for 5 hours. After completion, water (250 ml) was added. The aqueous phase was extracted with diethyl ether (3 x 100 mL). The organic phases were combined, dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification by flash column chromatography (SiO₂, pentane/EtOAc, 9:1) afforded compound **6** as white crystals (2.19 g, 41%). ¹H NMR (400 MHz, CDCl₃) δ 0.10 (s, 3H, CH₃), 0.12 (s, 3H, CH₃), 0.90 (s, 9H, C(CH₃)₃), 3.17 (bs, 1H, OH), 3.72 (dd, *J* = 5.5, 3.4, 1H, H₂), 3.74 (dd, *J* = 5.5, 4.0, 1H, H₂), 3.93 (dd, *J* = 5.5, 3.4, 1H, H₅), 3.96 (dd, *J* = 6.1, 3.4, 1H, H₅), 4.18 (m, 1H, H₆), 4.26 (app q, *J* = 5.3, 1H, H_{6a}), 4.41 (app t, *J* = 4.6, 1H, H_{3a}), 4.49 (app t, *J* = 5.6, 1H, H₃). ¹³C NMR (100 MHz, CDCl₃) δ -5.0 (CH₃), -4.6 (CH₃), 18.5 (C(CH₃)₃), 25.9 (C(CH₃)₃), 71.9 (C₆), 73.5 (C_{6a}), 74.3 (C₂), 75.8 (C₅), 81.7 (C₃), 82.2 (C_{3a}). NMR spectra were consistent with the literature.^[4]


(3*R*,6*S*)-6-Hydroxyhexahydrofuro[3,2-*b*]furan-3-yl acetate



In a round bottom flask under Ar, isosorbide (3.65 g, 25 mmol, 1.0 eq.), lead oxide (112 mg, 0.5 mmol, 0.02 eq.) and acetic anhydride (2.8 mL, 30.0 mmol, 1.2 eq.) were introduced. The mixture became viscous after 30 min and anhydrous DCM (5 mL) was added. Then the solution was allowed to stir for 2 h at r.t. The mixture was concentrated with toluene as co-solvent (3 x 20 mL) under reduced pressure to remove the unreacted acetic anhydride and the acetic acid formed. The crude was purified on flash column chromatography (SiO₂, DCM/MeOH, 95:5, R_f = 0.13) affording the title compound as a yellow


oil (4.11 g, 87%). ¹H NMR (400 MHz, CDCl₃) δ 2.04 (s, 3H, CH₃), 3.68 (dd, *J* = 5.3, 9.7, 1H, H₂), 3.75-3.88 (m, 3H, H₂, H₅), 4.22-4.23 (m, 1H, H₆), 4.31 (d, *J* = 4.6, 1H, H_{6a}), 4.75 (dd, *J* = 5.3, 4.6, 1H, H_{3a}), 5.04-5.08 (m, 1H, H₃). ¹³C NMR (101 MHz, CDCl₃) δ 20.6 (CH₃), 70.0 (C₂), 74.2 (C₃), 75.5 (C₅), 75.9 (C₆), 80.3 (C_{3a}), 88.1 (C_{6a}), 170.7 (C=O). MS (ESI/BS) [M + Na]⁺: calcd. for C₈H₁₂O₅Na: 211.1, found 211.0 [M + H]⁺: calcd. for C₈H₁₃O₅: 189.1, found 189.1.

(3*R*,6*S*)-6-((*Tert*-Butyldiphenylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-yl acetate



(3*R*,6*S*)-6-Hydroxyhexahydrofuro[3,2-*b*]furan-3-yl acetate (1.06 g, 5.63 mmol, 1.0 eq.) was introduced in a 25 mL round-bottom flask. After 3 cycles vacuum/N₂, anhydrous DMF (5 mL) and imidazole (0.58 g, 8.45 mmol, 1.5 eq.) were introduced under inert atmosphere. The solution was cooled to 0 °C and *tert*-butyl(chloro)diphenylsilane (2.2 mL, 8.45 mmol, 1.5 eq.) was added dropwise. At the end of the addition, the mixture was allowed to stir at r.t. for 22 h. The mixture turned white and two phases were obtained. An aqueous saturated solution of NH₄Cl (100 mL) was added to the mixture. Then, the aqueous layer was extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSO₄, filtrated and concentrated under reduced pressure. Purification of the residue was performed by flash column chromatography (SiO₂, Pentane/Et₂O, 8/2, R_f = 0.26) affording the title compound as a colorless oil (1.79 g, 75%). ¹H NMR (400 MHz, CDCl₃) δ 1.06 (s, 9H, 3 CH₃), 2.09 (s, 3H, CH₃-Ac), 3.61 (dd, *J* = 9.4, 6.5, 1H, H₂), 3.68 (dd, *J* = 9.7, 3.3, 1H, H₅), 3.84 (d, *J* = 9.7, 1H, H₅), 3.89 (dd, *J* = 9.4, 6.5, 1H, H₂), 4.30-4.31 (m, 1H, H₆), 4.40 (d, *J* = 4.2, 1H, H_{6a}), 4.88 (app t, *J* = 4.6, 1H, H_{3a}), 5.10 (app td, *J* = 6.5, 4.6, 1H, H₃), 7.33-7.49 (m, 6H, H_{Ph}), 7.59-7.67 (m, 4H, H_{Ph}). ¹³C NMR (101 MHz, CDCl₃) δ 20.8 (CH₃), 26.9 (3 CH₃), 69.5 (C₂), 74.4 (C₃), 76.0 (C₅), 77.9 (C₆), 80.6 (C_{3a}), 88.5 (C_{6a}), 127.9 and 128.0 (4 *m*-CH_{Ph}), 130.0 and 130.1 (2 *p*-CH_{Ph}), 133.3 and 133.5 (2 *C*_{qPh}), 135.8 (4 *o*-CH_{Ph}), 170.6 (C=O). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₄H₃₀O₅SiNa: 449.1755, found 449.1755.


(3*R*,6*S*)-6-((*Tert*-butyldiphenylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-ol (7)



(3*R*,6*S*)-6-((*tert*-Butyldiphenylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-ylacetate (1.0 g, 2.3 mmol, 1.0 eq.) was dissolved with EtOH (2 mL) in a 25 mL round-bottom flask. Then, KOH (0.2 g, 3.6 mmol, 1.5 eq., in 1.5 mL of EtOH) was added to the reaction mixture. The mixture was refluxed at 50 °C for 30 min. The solution obtained was cooled to r.t. and HCl (1M) was added until pH neutral. The aqueous layer was extracted with EtOAc (5 x 10 mL) and the organic layers were combined, dried over MgSO₄, filtrated and concentrated under reduced pressure. The crude was purified by flash column chromatography (SiO₂, Pentane/Et₂O, 1:1) affording the title compound **7** as a colorless oil (100 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ 1.08 (s, 9H, *t*-Bu), 2.65 (d, *J* = 7.8, 1H, OH), 3.41 (dd, *J* = 9.4, 6.3, 1H, H₂), 3.66 (dd, *J* = 9.7, 3.2, 1H, H₅), 3.81 (dd, *J* = 9.4, 6.3, 1H, H₂), 3.88 (d, *J* = 9.7, 1H, H₅), 4.23-4.32 (m, 1H, H₃), 4.34-4.37 (m, 1H, H₆), 4.39 (dt, *J* = 4.1, 1.0, 1H, H_{6a}), 4.70 (dd, *J* = 5.3, 4.1, 1H, H_{3a}),


7.36–7.48 (m, 6H, 6 H_{Ph}), 7.61–7.67 (m, 4H, 4 H_{Ph}). ¹³C NMR (101 MHz, CDCl₃) δ 19.3 (C_{qt-Bu}), 27.0 (3 C_{CH₃}), 72.5 (C₃), 73.5 (C₂), 76.0 (C₅), 78.3 (C₆), 81.9 (C_{3a}), 88.3 (C_{6a}), 127.9 and 128.0 (2 C_{Ph}), 130.09 and 130.13 (2 C_{Ph}), 133.2 and 133.5 (2 C_{qPh}), 135.76 and 135.77 (2 C_{Ph}). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₂H₂₈NaO₄Si: 407.1649 found 407.1642. [2M + Na]⁺: calcd. for C₄₄H₅₆NaO₈Si₂: 791.3406 found 791.3400.

(3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-yl acetate




In a 100 mL round bottom flask was added (3*R*,6*S*)-6-hydroxyhexahydrofuro[3,2-*b*]furan-3-yl acetate (1.5 g, 8.0 mmol, 1.0 eq.) in iodomethane (15 mL, 241 mmol, 30 eq.). Then, silver oxide (2.4 g, 10.4 mmol, 1.3 eq.) and calcium sulfate (6.0 g, 44 mmol, 5.5 eq.) were added to the mixture. The flask was protected from the light and the suspension was stirred for 2 days in the dark at r.t. The mixture was diluted with ether (100 mL) and filtered through a celite pad. The filtrate was concentrated under reduced pressure. The crude was purified on flash column chromatography (SiO₂, Pentane/Et₂O, 7/3, R_f = 0.13) affording the title compound as a yellowish oil (1.18 g, 73%). ¹H NMR (400 MHz, CDCl₃) δ 2.01 (s, 3H, CH₃), 3.27 (s, 3H, OCH₃), 3.65 (dd, *J* = 9.6, 5.6, 1H, H₂), 3.73–3.81 (m, 2H, H₅, H₆), 3.80–3.91 (m, 2H, H₅, H₂), 4.36 (d, *J* = 4.8, 1H, H_{6a}), 4.66 (app t, *J* = 4.8, 1H, H_{3a}), 5.03 (app q, *J* = 5.6, 1H, H₃). ¹³C NMR (101 MHz, CDCl₃) δ 20.5 (C_{CH₃}), 56.9 (O_CH₃), 69.8 (C₂), 72.7 (C₅), 74.0 (C₃), 80.4 (C_{3a}), 85.2 (C₆), 85.5 (C_{6a}), 170.1 (C=O). MS (ESI/BS) [M + Na]⁺: calcd. for C₉H₁₄O₅Na: 225.1, found 225.0, [M + H]⁺: calcd. for C₉H₁₅O₅: 203.1, found 203.1. NMR spectrum was consistent with the literature.^[3]

(3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-ol (**8**)




In a round bottom flask topped by a condenser, (3*R*,6*S*)-6-methoxyhexahydrofuro[3,2-*b*]furan-3-yl acetate (750 mg, 3.71 mmol, 1.0 eq.) was introduced in a solution of potassium hydroxide (312 mg, 5.56 mmol, 1.5 eq.) in EtOH (1M, 6 mL). The reaction mixture was stirred at 50 °C for 30 min. Then, the solution obtained was neutralized with aq. HCl (1M) until pH 7. The aqueous phase was extracted with EtOAc (5 x 10 mL). All the organic layers were collected and dried over MgSO₄. After filtration and concentration under reduced pressure, the crude was purified by flash column chromatography (SiO₂, Pentane/Et₂O, 7/3) affording the title compound **8** as a colorless oil (100 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ 2.64 (d, *J* = 7.0, 1H, OH), 3.39 (s, 3H, CH₃), 3.57 (dd, *J* = 9.5, 5.6, 1H, H₂), 3.79–3.96 (m, 3H, H₅, H₂), 4.05 (dd, *J* = 9.8, 1.1, 1H, H₆), 4.22–4.34 (m, 1H, H₃), 4.46 (dd, *J* = 4.8, 1.1, 1H, H_{6a}), 4.60 (app t, *J* = 4.8, 1H, H_{3a}). ¹³C NMR (101 MHz, CDCl₃) δ 57.3 (C_{CH₃}), 72.4 (C₃), 73.1 (C₆), 73.8 (C₂), 81.9 (C_{3a}), 85.6 (C_{6a}), 85.8 (C₅). MS (ESI/BS) [M + Na]⁺: calcd. for C₇H₁₂O₄Na: 183.2, found 183.1, [M + H]⁺: calcd. for C₇H₁₃O₄: 161.2, found 161.1. NMR spectrum was consistent with the literature.^[3]

(3*R*,6*S*)-6-(*Tert*-butoxy)hexahydrofuro[3,2-*b*]furan-3-ol (**9**)



In a 50 mL round bottom flask was introduced isosorbide (5.0 g, 34.2 mmol, 1.0 eq.) and dissolved in *tert*-butanol (20.3 g, 274 mmol, 8 eq.). Then, Amberlyst-15 (2g, ratio $m_{\text{amberlyst}}/m_{\text{isosorbide}} = 0.4$) was added and the reaction mixture was refluxed at 70 °C for 6 h. The Amberlyst was filtered off, washed by DCM (200 mL) and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (SiO₂, Pentane/Et₂O, 6/4) affording the title compound **9** as a yellow liquid (0.85 g, 12%). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9H, 3 CH₃), 2.67 (d, *J* = 7.4, 1H, OH), 3.52–3.57 (m, 1H, H₂), 3.77–3.88 (m, 2H, H₅, H₂), 3.92–3.97 (m, 1H, H₅), 4.11–4.18 (m, 1H, H₆), 4.20–4.30 (m, 1H, H₃), 4.33 (app d, *J* = 4.6, 1H, H_{6a}), 4.58 (dd, *J* = 5.1, 4.6, 1H, H_{3a}). ¹³C NMR (101 MHz, CDCl₃) δ 28.3 (3C_{CH₃}), 72.4 (C₃), 73.4 (C₂), 74.8 (C(CH₃)₃), 75.8 (C₅), 76.9 (C₆), 81.7 (C_{3a}), 88.8 (C_{6a}). MS (ESI/BS) [M + Na]⁺: calcd. for C₁₀H₁₈O₄Na: 225.2, found 225.1, [2M + Na]⁺: calcd. for C₂₀H₃₆O₈Na: 427.5, found 427.2. NMR spectrum was consistent with the literature.^[5]

5-Methyltetrahydrofuran-3-ol




In a 50 mL round-bottom flask, under nitrogen, was introduced 4-penten-2-ol (0.50 g, 5.81 mmol, 1.0 eq.) and triethylamine (2.30 mL, 8.72 mmol, 1.5 eq.) in anhydrous DCM (15 mL) at 0 °C. Then, *p*-toluenesulfonyl chloride (1.66 g, 8.72 mmol, 1.5 eq.) and DMAP (0.07 g, 0.58 mmol, 10 mol%) were added sequentially under inert atmosphere in the cooled solution. The reaction mixture was allowed to warm up to r.t. and stirred overnight. After completion, an aqueous saturated solution of NH₄Cl (30 mL) was added to the mixture and the aqueous phase was extracted with DCM (3 x 10 mL). The organic phases were washed with a brine solution (50 mL), dried over Na₂SO₄, filtrated and concentrated under reduced pressure. Filtration through silica column with DCM gave 4-penten-2-tosylate as a colorless oil (1.36 g, 97%). CAS: 52753-86-3. NMR spectra were consistent with the literature.^[6]

To a stirred solution of OsO₄ (0.05 mL, 4%wt/H₂O, 0.5 mol%) and NMO (194 mg, 1.66 mmol, 1.0 eq.) in *t*-BuOH/H₂O (15 mL, 1:1) at 0 °C was added 4-penten-2-tosylate (400 mg, 1.66 mmol, 1.0 eq.). The solution obtained was allowed to warm up to r.t. and was stirred for 24 h. After the addition of solid sodium sulfite (800 mg), the reaction mixture was stirred for an additional 1 h. The mixture was extracted with EtOAc (3 x 10 mL). The organic layers were dried over Na₂SO₄, filtrated and concentrated. The crude obtained was purified by flash column chromatography (SiO₂, Pentane/EtOAc, 1:1) and gave the title compound as a mixture of two diastereoisomers (117 mg, 70%, dr 57:43 determined by ¹H NMR). ¹H NMR (400 MHz, CDCl₃) δ 1.26 (d, *J* = 6.1, 3H, CH₃, dia 1), 1.35 (d, *J* = 6.1, 3H, CH₃, dia 2), 1.48 (dddd, *J* = 13.4, 7.5, 3.0, 1.3, 1H, H₄, dia 2), 1.60 (ddd, *J* = 13.3, 9.7, 5.6, 1H, H₄, dia 1), 1.77 (bd, *J* = 4.4, 1H, OH, dia 1), 1.81 (bd, *J* = 6.4, 1H, OH, dia 2), 2.00 (app ddt, *J* = 13.3, 5.5, 1.2, 1H, H₄, dia 1), 2.37 (ddd, *J* = 13.4, 7.5, 6.7, 1H, H₄, dia 2), 3.63–3.72 (m, 2H, 2 H₂, dia 1 and 2), 3.85 (app. dt, *J* = 10.0, 1.6, 1H, H₂, dia 2), 3.95 (app tq, *J* = 7.5, 6.2, 1H, H₅, dia 2), 4.06 (dd, *J* = 9.9, 4.6, 1H, H₂, dia 1), 4.18–4.31 (m, 1H, H₄, dia 1), 4.45 (bs, 1H, H₁, dia 2), 4.51 (bs, 1H, H₁, dia 1). ¹³C NMR (101 MHz, CDCl₃) δ 20.7 (C_{CH₃}, dia 1), 21.8 (C_{CH₃}, dia 2), 43.2 (C₄, dia 2), 43.6 (C₄, dia 1), 73.1 (C₅, dia 1), 73.2 (C₅, dia 2), 74.1 (C₂, dia 1), 75.2 (C₂, dia 2),


75.6 (C₃, dia 1), 75.8 (C₃, dia 2). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₅H₁₀NaO₂: 125.0573, found 125.0575. CAS: 29848-43-9. Journal of Catalysis (1999), 182(2), 349-356.

(3*R*,4*S*)-4-Methyltetrahydrofuran-3-ol (±)



To a solution of CuI (273 mg, 1.4 mmol, 20 mol%), under Argon, in THF [0.5M] was added methyl magnesium bromide (3 M in THF, 4.8 mL, 14.3 mmol, 2 eq.) at - 78 °C. The resulting solution was stirred at - 78 °C before the addition of 3,6-dioxabicyclo[3.1.0]hexane (500 μL, 7.2 mmol, 1 eq.). The mixture was then allowed to warm up to r.t. and stirred for 18 h. The mixture obtained was quenched with a saturated aqueous ammonium chloride solution (15 mL). Then, diluted with water (15 mL) and extracted with diethyl ether (5 x 30 mL). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification by flash chromatography (SiO₂, dichloromethane/methanol, 10/1) afforded the title compound (105 mg, 14% yield) as a slight yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 1.03 (d, *J* = 7.1, 3H, Me), 2.16–2.24 (m, 1H, H₄), 3.41 (dd, *J* = 8.5, 4.6, 1H, H₅), 3.70 (dd, *J* = 9.8, 2.3, 1H, H₂), 3.91 (dd, *J* = 9.8, 4.7, 1H, H₂), 4.02 (app dt, *J* = 4.7, 2.3, 1H, H₃), 4.11 (dd, *J* = 8.5, 6.5, 1H, H₅). ¹³C NMR (101 MHz, CDCl₃) δ 16.7 (C_{Me}), 42.9 (C₄), 73.9 (C₅), 74.5 (C₂), 78.8 (C₃). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₅H₁₀O₂Na: 125.0573, found 125.0574. CAS: 387357-58-6. NMR spectra were consistent with the literature.^[7]


(3*R*,4*S*)-4-Propyltetrahydrofuran-3-ol (±)



To a solution of CuI (82 mg, 0.43 mmol, 20 mol%), under Argon, in THF (1 mL) was added propyl magnesium chloride (1.6 mL, 3.23 mmol, 2 M in Et₂O, 1.5 eq.), at - 30 °C. The resulting solution was stirred at - 30 °C before the addition of 3,6-dioxabicyclo[3.1.0]hexane (150 μL, 2.16 mmol, 1.0 eq.). The mixture was then allowed to warm up to r.t. and stirred for 16 h. The mixture obtained was quenched with a saturated aqueous ammonium chloride solution (5 mL). Then, diluted with water (10 mL) and extracted with diethyl ether (4 x 5 mL). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification by flash chromatography (SiO₂, EtOAc, 100%) afforded the title compound (254 mg, 90%) as a pale-yellow liquid.

¹H NMR (300 MHz, CDCl₃) δ 0.95 (t, *J* = 7.0, 3H, CH₃), 1.21–1.52 (m, 4H, 2 CH₂), 1.81 (bs, 1H, OH), 2.10 (m, 1H, H₄), 3.46 (dd, *J* = 8.7, 5.3, 1H, H₅), 3.72 (dd, *J* = 9.8, 2.4, 1H, H₂), 3.87 (dd, *J* = 9.8, 4.6, 1H, H₂), 4.04–4.18 (m, 2H, H₃, H₅). ¹³C NMR (75 MHz, CDCl₃) δ 14.1 (CH₃), 21.2 (CH₂), 34.0 (CH₂), 48.5 (C₄), 72.5 (C₅), 74.6 (C₂), 77.6 (C₃). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₇H₁₄O₂Na: 153.0886, found: 153.0888.


(3*S*,4*S*)-4-Methoxytetrahydrofuran-3-ol (±)



Sodium (830 mg, 36 mmol, 13 eq.) was carefully introduced in a flask containing freshly distilled MeOH (7 mL) at 0 °C under inert atmosphere. After vigorous stirring and complete dissolution of solid sodium, 3,6-dioxabicyclo[3.1.0]hexane (243 mg, 2.82 mmol, 1.0 equiv.) in MeOH (1M, 2.8 mL) was added dropwise. The mixture obtained was heated at 45 °C for 14 h. Then, the solution was cooled down to 0 °C and acetic acid was added until pH 7. The reaction mixture was concentrated and the solid obtained was taken in EtOAc. The organic phase obtained was washed with NaHCO₃ (15 mL), dried over Na₂SO₄





and concentrated *in vacuo*. The purification was performed by flash column chromatography on silica gel using EtOAc as eluent affording the title compound as a colorless syrup (245 mg, 74%). ¹H NMR (400 MHz, CDCl₃) δ 3.38 (s, 3H, OMe), 3.69–3.82 (m, 3H, H₂, H₄, H₅), 3.93 (dd, *J* = 10.0, 3.9, 1H, H₂), 4.05 (dd, *J* = 9.7, 4.4, 1H, H₅), 4.29 (ddd, *J* = 3.9, 1.8, 1.3, 1H, H₃). ¹³C NMR (101 MHz, CDCl₃) δ 57.3 (OMe), 71.3 (C₅), 74.0 (C₂), 75.1 (C₃), 87.0 (C₄). MS (ESI/HRMS) [M + H]⁺: calcd. for C₅H₁₁O₃: 119.0703, found 119.0703, [M + Na]⁺: calcd. for C₅H₁₀O₃Na: 141.0522, found 141.0522.

(3*R*)-Hexahydrofuro[3,2-*b*]furan-3-ol




Isosorbide (3.0 g, 20.5 mmol, 1.0 eq.) was dissolved in dry DCM (20 mL) and Et₃N (1.1 mL, 8.2 mmol, 0.4 eq.) was added to the solution at r.t. Then, *O*-phenyl carbonochloridothioate (0.9 mL, 6.2 mmol, 0.3 eq.) was introduced dropwise and the reaction was stirred for 18 h at r.t. After completion of the reaction, the mixture was diluted with DCM (100 mL) and saturated aq. solution of NaHCO₃ (100 mL) was added. Then, the aqueous phase was extracted with DCM (3 x 30 mL). The organic phases were combined, washed with H₂O (100 mL), brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (SiO₂, pentane/EtOAc, 1/1) to give the title compound as a white solid (383 mg, 22%). In a round bottom flask, under N₂, Tributyltin hydride (720 μL, 2.71 mmol, 2 eq.) and AIBN (22 mg, 0.136 mmol, 10 mol%) were refluxed in PhMe (10 mL) for 10 min. Then, *O*-((3*S*,6*R*)-6-hydroxyhexahydrofuro[3,2-*b*]furan-3-yl) *O*-phenyl carbonothioate (383 mg in 5 mL of PhMe, 1.36 mmol, 1 eq.) was added to the refluxed solution with an addition funnel over a period of 1 h. After complete addition, the reaction mixture was allowed to stir for 5 h at 110 °C. Then, the mixture was cooled at r.t. and the solvent was removed *in vacuo*. To the liquid obtained were added pentane (20 mL) and acetonitrile (20 mL) and the two phases were separated. The pentane phase was extracted with acetonitrile (3 x 20 mL). The acetonitrile layers were combined and concentrated under reduced pressure. The crude was purified on flash column chromatography (SiO₂, pentane/EtOAc, 1/1) affording the title compound as a colorless liquid (96 mg, 54%). ¹H NMR (300 MHz, CDCl₃) δ 2.02 (dddd, *J* = 13.4, 10.6, 8.2, 4.9, 1H, H₆), 2.15 (dddd, *J* = 13.4, 5.8, 2.6, 1.3, 1H, H₆), 2.76 (d, *J* = 6.3, 1H, OH), 3.67 (dd, *J* = 9.7, 4.9, 1H, H₂), 3.76–3.90 (m, 2H, H₂, H₅), 4.05 (td, *J* = 8.2, 2.6, 1H, H₅), 4.25 (m, 1H, H₃), 4.47 (dd, *J* = 5.7, 4.9, 1H, H_{3a}), 4.59 (app td, *J* = 4.9, 1.3, 1H, H_{6a}). ¹³C NMR (75 MHz, CDCl₃) δ 34.7 (C₆), 69.7 (C₅), 72.4 (C₃), 74.5 (C₂), 82.6 (C_{3a}), 83.4 (C_{6a}). MS (ESI/HR) [M + H]⁺: calcd. for C₆H₁₀O₃Na: 153.0522, found 153.0522.

Blank reactions:




Products obtained from BH

2-((3*R*,6*S*)-6-(Benzyloxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (**2**)



(3*R*,6*S*)-6-(Benzyloxy)hexahydrofuro[3,2-*b*]furan-3-ol **1** (59 mg, 0.25 mmol, 1.0 eq.), pentamethylacetophenone (52 mg, 0.275 mmol, 1.1 eq.), NaO^tBu (48 mg, 0.50 mmol, 2 eq.), [Cp*Ir(Ts*-dpen)(*R,R*)] (19 mg, 0.025 mmol, 10 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 95:5 to 80:20) afforded the title compound **2** as a yellow solid (18 mg, 18%, dr >99:1). ¹H NMR (400 MHz, CDCl₃) δ 2.10 (s, 6H, 2 CH₃), 2.18 (s, 6H, 2 CH₃), 2.23 (s, 3H, CH₃), 2.66–2.87 (m, 2H, H₂, H_{3'}), 3.02–3.18 (m, 1H, H₂), 3.37 (dd, *J* = 10.6, 7.9, 1H, H_{2'}), 3.82 (dd, *J* = 10.0, 4.2, 1H, H_{5'}), 3.88 (dd, *J* = 10.0, 2.6, 1H, H_{5'}), 4.05 (ddd, *J* = 4.2, 2.6, 1.2, 1H, H_{6'}), 4.17 (app t, *J* = 7.9, 1H, H_{2'}), 4.57 (d, *J* = 11.9, 1H, CH₂Ph), 4.63 (d, *J* = 11.9, 1H, CH₂Ph), 4.63 (dd, *J* = 4.0, 1.2, 1H, H_{6'a}), 4.82 (app t, *J* = 4.0, 1H, H_{3'a}), 7.27–7.38 (m, 5H, H_{Ar}). ¹³C NMR (101 MHz, CDCl₃) δ 16.1 (2 CH₃), 16.8 (CH₃), 17.3 (2 CH₃), 40.1 (C_{3'}), 42.4 (C₂), 71.7 (CH₂Ph), 72.0 (C_{2'}), 73.0 (C_{5'}), 83.4 (C_{3'a}), 84.0 (C_{6'}), 86.9 (C_{6'a}), 127.4 (2 C_{qAr}), 127.9 (2 CH_{Ph}), 128.0 (CH_{Ph}), 128.6 (2 CH_{Ph}), 133.2 (2 C_{qAr}), 135.6 (C_{qAr}), 137.9 (C_{qPh}), 140.3 (C_{qAr}), 210.6 (C₁). IR (ATR) ν 697, 736, 903, 929, 1012, 1028, 1096, 1206, 1273, 1306, 1382, 1453, 1697, 2864, 2925. $[\alpha]_D^{21} = +26.7^\circ$ (c 0.25 CHCl₃). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₆H₃₂O₄Na: 431.2193, found 431.2198, [M + H]⁺: calcd. for C₂₆H₃₃O₄: 409.2373, found 409.2380.


2-((3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (**10**)



(3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-ol **8** (50 mg, 0.31 mmol, 1.0 eq.), pentamethylacetophenone (65 mg, 0.34 mmol, 1.1 eq.), NaO^tBu (60 mg, 0.62 mmol, 2 eq.) and [Ir-Noyo(*R,R*)] (12 mg, 0.0155 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 8/2) afforded the title compound **10** as a yellow solid (18 mg, 17%). ¹H NMR (400 MHz, CDCl₃) δ 2.10 (s, 6H, 2 CH₃), 2.17 (s, 6H, 2 CH₃), 2.22 (s, 3H, CH₃), 2.68–2.83 (m, 2H, H_{3'}, H₂), 3.09 (dd, *J* = 18.2, 6.1, 1H), 3.36 (dd, *J* = 10.9, 8.1, 1H, H_{2'}), 3.40 (s, 3H, OMe), 3.75–3.90 (m, 3H, 2 H_{5'}, H_{6'}), 4.17 (app t, *J* = 8.1, 1H, H_{2'}), 4.57 (dd, *J* = 4.4, 1.1, 1H, H_{6'a}), 4.77 (app t, *J* = 4.4, 1H, H_{3'a}). ¹³C NMR (101 MHz, CDCl₃) δ 16.1 (2 CH₃), 16.8 (CH₃), 17.3 (2 CH₃), 40.1 (C_{3'}), 42.4 (C₂), 57.4 (C_{OMe}), 72.0 (C_{2'}), 72.6 (C_{5'}), 83.3 (C_{3'a}), 86.2 and 86.4 (C_{6'a}, C_{6'}), 127.4 (2 C_{qAr}), 133.2 (2 C_{qAr}), 135.6 (C_{qAr}), 140.3 (C_{qAr}), 210.6 (C₁). IR (ATR) ν 860, 887, 932, 1006, 1092, 1193, 1233, 1258, 1306, 1365, 1391, 1463, 1702, 1766, 2867, 2935, 2972. $[\alpha]_D^{21} =$


+ 46.5 ° (*c* 0.12 CHCl₃). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₀H₂₈O₄Na: 355.1880, found 355.1880, [M + H]⁺: calcd. for C₂₀H₂₉O₄: 333.2060, found 333.2062.

2-((3*R*,6*S*)-6-(*Tert*-Butoxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12)




(3*R*,6*S*)-6-(*Tert*-Butoxy)hexahydrofuro[3,2-*b*]furan-3-ol **9** (91 mg, 0.45 mmol, 1.0 eq.), pentamethylacetophenone (94 mg, 0.495 mmol, 1.1 eq.), NaO^tBu (43 mg, 0.45 mmol, 1 eq.) and [Cp*Ir(Ts*-dpen)(*R,R*)] (6.7 mg, 0.01 mmol, 2 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 95:5 to 90:10) afforded the title compound **12** as a yellow solid (79 mg, 47%, dr >99:1). ¹H NMR (400 MHz, CDCl₃) δ 1.22 (s, 9H, ^tBu-CH₃), 2.10 (s, 6H, 2 CH₃), 2.17 (s, 6H, 2 CH₃), 2.22 (s, 3H, CH₃), 2.64–2.87 (m, 2H, H₂, H₃), 3.09 (dd, *J* = 21.0, 8.7, 1H, H₂), 3.37 (dd, *J* = 10.3, 7.9, 1H, H₂), 3.61 (dd, *J* = 9.4, 3.5, 1H, H₅), 3.86 (dd, *J* = 9.4, 5.0, 1H, H₅), 4.07 (ddd, *J* = 5.0, 3.5, 1.6, 1H, H₆), 4.15 (app t, *J* = 7.9, 1H, H₂), 4.43 (dd, *J* = 4.0, 1.6, 1H, H_{6'a}), 4.74 (app t, *J* = 4.0, 1H, H_{3'a}). ¹³C NMR (101 MHz, CDCl₃) δ 16.1 (2 CH₃), 16.8 (2 CH₃), 17.3 (CH₃), 28.4 (3 CH₃), 40.0 (C_{3'}), 42.4 (C₂), 71.6 (C_{2'}), 74.5 (C(CH₃)₃), 74.9 (C_{5'}), 77.3 (C_{6'}), 83.3 (C_{3'a}), 89.7 (C_{6'a}), 127.4 (2 C_{qAr}), 133.2 (2 C_{qAr}), 135.6 (C_{qAr}), 140.4 (C_{qAr}), 210.7 (C₁). IR (ATR) ν 825, 890, 940, 1021, 1070, 1112, 1138, 1198, 1365, 1391, 1458, 1702, 2347, 2870, 2939, 2975. [α]_D²¹ = + 72.7° (*c* 0.47 CHCl₃). MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₃H₃₄O₄Na: 397.2349, found 397.2330, [M + H]⁺: calcd. for C₂₃H₃₅O₄: 375.2530, found 375.2512.

1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13)



Tetrahydrofuran-3-ol (22 mg, 0.25 mmol, 1.0 eq.), pentamethylacetophenone (52 mg, 0.275 mmol, 1.1 eq.), NaO^tBu (48 mg, 0.50 mmol, 2.0 eq.), [Cp*IrCl₂]₂ (10 mg, 0.013 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash column chromatography (SiO₂, solid load, pentane/Et₂O, 8/2) afforded the title compound **13** as a yellow solid (65 mg, >99%). ¹H NMR (400 MHz, CDCl₃) δ 1.50–1.64 (m, 1H, H₄), 2.08–2.12 (m, 6H, 2 CH₃), 2.18 (s, 6H, 2 CH₃), 2.23 (s, 3H, CH₃), 2.20–2.31 (m, 1H, H₄), 2.70–2.91 (m, 3H, 2 H₂, H₃), 3.40–3.49 (m, 1H, H₂), 3.78 (app dt, *J* = 8.4, 7.4, 1H, H₅), 3.86 (app td, *J* = 8.4, 4.9, 1H, H₅), 4.04–4.12 (m, 1H, H₂). ¹³C NMR (101 MHz, CDCl₃) δ 16.1 (2 CH₃), 16.8 (CH₃), 17.3 (2 CH₃), 32.5 (C_{4'}), 34.1 (C_{3'}), 49.7 (C₂), 67.8 (C_{5'}), 73.3 (C_{2'}), 127.3 (2 C_{qAr}), 133.3 (2 C_{qAr}), 135.7 (C_{qAr}), 140.3 (C_{qAr}), 210.9 (C₁). IR (ATR) ν 663, 903, 934, 1057, 1070, 1129, 1362, 1402, 1448, 1695, 2870, 2941. MS (ESI/HRMS) [M + Na]⁺: calcd. for C₁₇H₂₄O₂Na: 283.1669, found 283.1664, [M + H]⁺: calcd. for C₁₇H₂₅O₂: 261.1849, found 261.1846.

2-(5-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (14)



5-Methyltetrahydrofuran-3-ol (26 mg, 0.25 mmol, 1.0 eq.), pentamethylacetophenone (52 mg, 0.275 mmol, 1.1 eq.), NaO^tBu (48 mg, 0.50 mmol, 2 eq.), [Cp*IrCl₂]₂ (10 mg, 0.0125 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, Pentane/EtOAc, 95/5 to 80/20) afforded the title compound **14** as a yellow solid, (44 mg, 64%, dr 61:39 determined by ¹H NMR).


Major isomer:

¹H NMR (400 MHz, CDCl₃) δ 1.12 (ddd, *J* = 12.3, 9.4, 8.3, 1H, H_{4'}), 1.27 (d, *J* = 5.9, 3H, Me), 2.10 (s, 6H, 2 CH₃), 2.18 (s, 6H, 2 CH₃), 2.23 (s, 3H, CH₃), 2.37 (ddd, *J* = 12.3, 6.9, 5.8, 1H, H_{4'}), 2.71–2.93 (m, 3H, 2 H₂, H_{3'}), 3.57 (dd, *J* = 8.7, 6.2, 1H, H_{2'}), 3.99 (dq, *J* = 9.4, 5.9, 5.8, 1H, H_{5'}), 4.04–4.12 (m, 1H, H_{2'}). ¹³C NMR (101 M, CDCl₃) δ 16.1 (2 CH₃), 16.8 (CH₃), 17.3 (2 CH₃), 21.1 (C_{Me}), 35.0 (C_{3'}), 40.6 (C_{4'}), 50.4 (C₂), 72.9 (C_{2'}), 75.7 (C_{5'}), 127.3 (2 C_{qAr}), 133.3 (2 C_{qAr}), 135.7 (C_{qAr}), 140.3 (C_{qAr}), 211.0 (C₁).

Minor isomer:

¹H NMR (400 MHz, CDCl₃) δ 1.25 (d, *J* = 6.1, 3H, Me), 1.73 (ddd, *J* = 12.6, 7.0, 5.6, 1H, H_{4'}), 1.84 (ddd, *J* = 12.6, 8.3, 6.9, 1H, H_{4'}), 2.10 (s, 6H, 2 CH₃), 2.18 (s, 6H, 2 CH₃), 2.23 (s, 3H, CH₃), 2.71–2.93 (m, 3H, 2 H₂, H_{3'}), 3.40 (dd, *J* = 8.8, 6.6, 1H, H_{2'}), 4.04–4.12 (m, 3H, H_{5'}), 4.23 (dd, *J* = 8.8, 6.8, 1H, H_{2'}). ¹³C NMR (101 M, CDCl₃) δ 16.1 (2 CH₃), 16.8 (CH₃), 17.3 (2 CH₃), 21.4 (C_{Me}), 34.0 (C_{3'}), 39.4 (C_{4'}), 49.7 (C₂), 73.3 (C_{2'}), 74.6 (C_{5'}), 127.3 (2 C_{qAr}), 133.3 (2 C_{qAr}), 135.7 (C_{qAr}), 140.3 (C_{qAr}), 210.9 (C₁). IR (ATR) ν 660, 749, 806, 822, 898, 935, 1024, 1039, 1090, 1108, 1133, 1275, 1302, 1353, 1378, 1402, 1451, 1698, 2871, 2928, 2970. MS (ESI/HRMS) [M + Na]⁺: calcd. for C₁₈H₂₆O₂Na: 297.1825, found 297.1823, [M + H]⁺: calcd. for C₁₈H₂₇O₂: 275.2006, found 275.2008.

2-(4-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (15)



(3*R*,4*S*)-4-Methyltetrahydrofuran-3-ol (23 mg, 0.23 mmol, 1.0 eq.), pentamethylacetophenone (48 mg, 0.25 mmol, 1.1 eq.), NaO^tBu (44 mg, 0.46 mmol, 2.0 eq.), [Cp*Ir(Ts-dpen)(*R,R*)] (8.6 mg, 0.0115 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 9/1) afforded the title compound **15** as a yellow solid, (41 mg, 65%, dr 70:30 determined by ¹H NMR).


Major isomer:

¹H NMR (400 MHz, CDCl₃) δ 0.94 (d, *J* = 7.1, 3H, Me), 2.10 (s, 6H, 2 CH₃), 2.19 (s, 6H, 2 CH₃), 2.24 (s, 3H, CH₃), 2.41–2.51 (m, 1H, H_{4'}), 2.59–2.71 (m, 1H, H₂), 2.75–2.88 (m, 2H, H₂, H_{3'}), 3.44 (dd, *J* = 8.2, 5.1, 1H, H_{5'}), 3.56 (dd, *J* = 8.5, 7.0, 1H, H_{2'}), 3.93–3.99 (m, 1H, H_{5'}), 4.16 (dd, *J* = 8.5, 7.1, 1H, H_{2'}). ¹³C NMR (101 MHz, CDCl₃) δ 13.5 (C_{Me}), 16.10 (2 CH₃), 16.8 (CH₃), 17.32 (2 CH₃), 35.8 (C_{4'}), 37.2 (C_{3'}), 44.2 (C₂), 72.6 (C_{2'}), 74.8 (C_{5'}), 127.34 (2 C_{qAr}), 133.34 (2 C_{qAr}), 135.74 (C_{qAr}), 140.5 (C_{qAr}), 211.0 (C₁).

Minor isomer:

¹H NMR (400 MHz, CDCl₃) δ 1.08 (d, *J* = 6.7, 3H, Me), 1.85–1.96 (m, 1H, H_{4'}), 2.09 (s, 6H, 2 CH₃), 2.18 (s, 6H, 2 CH₃), 2.23 (s, 3H, CH₃), 2.27–2.36 (m, 1H, H_{3'}), 2.59–2.71 (m, 1H, H₂), 2.97 (dd, *J* = 18.9, 4.2, 1H, H₂), 3.34 (app t, *J* = 8.1, 1H, H_{5'}), 3.51 (dd, *J* = 8.8, 7.1, 1H, H₂), 3.96 (m, 1H, H_{5'}), 4.28 (dd, *J* = 8.8, 7.4, 1H, H₂). ¹³C NMR (101 MHz, CDCl₃) δ 16.09 (2 CH₃), 16.5 (C_{Me}), 16.8 (CH₃), 17.29 (2 CH₃), 39.9 (C_{4'}), 42.0 (C_{3'}), 49.1 (C₂), 73.8 (C_{2'}), 74.6 (C_{5'}), 127.30 (2 C_{qAr}), 133.31 (2 C_{qAr}), 135.72 (C_{qAr}), 140.4 (C_{qAr}), 211.1 (C₁). IR (ATR) ν 650, 922, 995, 1038, 1099, 1311, 1386, 1403, 1460, 1694, 2854, 2930, 2961. MS (ESI/HRMS) [M + Na]⁺: calcd. for C₁₈H₂₆O₂Na: 297.1825, found 297.1820, [M + H]⁺: calcd. for C₁₈H₂₇O₂: 275.2006, found 275.2001.


1-(2,3,4,5,6-Pentamethylphenyl)-2-(4-Propyltetrahydrofuran-3-yl)ethanone (16)



(3*R*,4*S*)-4-Propyltetrahydrofuran-3-ol (+/-) (33 mg, 0.25 mmol, 1.0 eq.), pentamethylacetophenone (52 mg, 0.275 mmol, 1.1 eq.), NaO^tBu (48 mg, 0.50 mmol, 2 eq.), [Cp*Ir(Ts*-dpen)(*R,R*)] (9.4 mg, 0.0125 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 95:5 to 80:20) afforded the title compound **16** as a brown oil (53 mg, 70%, dr 1:1). The diastereoisomers were assigned when it was possible due to the overlap signals.

¹H NMR (400 MHz, CDCl₃) δ 0.91 (m, 6H, 2 CH₂CH₂CH₃, dia 1 and 2), 1.18–1.41 (m, 7H, 2 CH₂CH₂CH₃, CH₂CH₂CH₃, dia 1 and 2), 1.53–1.81 (m, 2H, CH₂CH₂CH₃, H_{4'}), 2.10 (s, 6H, 2 CH₃), 2.11 (s, 6H, 2 CH₃), 2.19 (2 s, 12H, 4 CH₃), 2.24 (2 s, 6H, 2 CH₃), 2.28–2.46 (m, 2H, H_{3'}, H_{4'}), 2.66 (m, 2H, 2 H₂), 2.75–2.87 (m, 2H, H_{3'}, H₂), 2.97 (dd, *J* = 18.9, 3.8, 1H, H₂), 3.35–3.47 (m, 2H, 2 H_{5'}), 3.52 (dd, *J* = 8.8, 6.5, 1H, H₂, dia 1), 3.67 (dd, *J* = 8.7, 4.4, 1H, H₂, dia 2), 3.95 (m, 2H, 2 H_{5'}), 4.11 (ddd, *J* = 8.7, 6.0, 1.0, 1H, H₂, dia 2), 4.24 (dd, *J* = 8.8, 7.3, 1H, H₂, dia 1). ¹³C NMR (75 MHz, CDCl₃) δ 14.38 and 14.40 (CH₂CH₂CH₃, dia 1 and 2), 16.1 (4 CH₃), 16.8 (2 CH₃), 17.22 and 17.24 (4 CH₃), 21.66 and 21.75 (CH₂CH₂CH₃, dia 1 and 2), 30.2 (CH₂CH₂CH₃, dia 1), 35.1 (CH₂CH₂CH₃, dia 2), 36.5 and 40.5 (C_{3'}), 41.6 (C_{4'}), 43.8 (C₂, dia 2), 45.1 (C_{4'}), 49.8 (C₂, dia 1), 72.3; 73.3; 73.5; 73.8 (2 C_{2'}, 2 C_{5'}), 127.28 and 127.33 (4 C_{qAr}), 133.26 and 133.31 (4 C_{qAr}), 135.66 and 135.69 (2 C_{qAr}), 140.3 (C_{qAr}), 140.6 (C_{qAr}), 211.1 (2 C₁). IR (ATR) ν 656, 694, 906, 933, 1000, 1027, 1051, 1101, 1315, 1381, 1401, 1465, 1698, 2870, 2927, 2956. MS (ESI/HRMS) [M + Na]⁺: calcd. for C₂₀H₃₀O₂Na: 325.2138, found 325.2138, [M + H]⁺: calcd. for C₂₀H₃₁O₂: 303.2319, found 303.2321.


2-((3*R*,4*R*)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17)



(3*S*,4*S*)-4-Methoxytetrahydrofuran-3-ol (32 mg, 0.27 mmol, 1 eq.), pentamethylacetophenone (52 mg, 0.275 mmol, 1 eq.), NaO^tBu (48 mg, 0.50 mmol, 2 eq.), [Cp*Ir(Ts*-dpen)(*R,R*)] (9.4 mg, 0.0125 mmol, 5 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO₂, solid load, pentane/EtOAc, 9/1) afforded the title compound **17** as a yellowish solid, (23 mg, 29%, dr >99:1, determined by ¹H NMR). After recrystallization from Et₂O/pentane at r.t. colourless needle crystals suitable for X-ray crystallography were obtained.


^1H NMR (400 MHz, CDCl_3) δ 2.12 (s, 6H, 2 CH_3), 2.19 (s, 6H, 2 CH_3), 2.23 (s, 3H, CH_3), 2.72 (dd, $J = 19.0, 5.7$, 1H, H_2), 2.80 (m, 1H, H_3), 3.10 (dd, $J = 19.0, 7.7$, 1H, H_2), 3.30 (s, 3H, OCH_3), 3.52 (dd, $J = 9.7, 7.9$, 1H, H_2), 3.86 (dd, $J = 10.0, 3.7$, 1H, H_5), 3.97 (dd, $J = 10.0, 1.4$, 1H, H_5), 4.05–4.12 (m, 2H, H_2 , H_4). ^{13}C NMR (101 MHz, CDCl_3) δ 16.1 (2 $\underline{\text{C}}\text{H}_3$), 16.8 ($\underline{\text{C}}\text{H}_3$), 17.1 (2 $\underline{\text{C}}\text{H}_3$), 38.8 (C_3), 42.1 (C_2), 57.0 (C_{Me}), 71.4 (C_2), 71.7 (C_5), 81.2 (C_4), 127.4 (2 C_{qAr}), 133.2 (2 C_{qAr}), 135.6 (C_{qAr}), 140.5 (C_{qAr}), 211.0 (C_1). IR (ATR) ν 648, 713, 754, 838, 898, 937, 966, 1043, 1081, 1100, 1114, 1167, 1190, 1221, 1310, 1374, 1398, 1450, 1697, 1732, 2857, 2887, 2920. MS (ESI/HRMS) $[\text{M} + \text{Na}]^+$: calcd. for $\text{C}_{18}\text{H}_{26}\text{O}_3\text{Na}$: 313.1774, found 313.1772, $[\text{M} + \text{H}]^+$: calcd. for $\text{C}_{18}\text{H}_{27}\text{O}_3$: 291.1955, found 291.1954.

2-((3R)-Hexahydrofuro[3,2-b]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18)



(3R)-Hexahydrofuro[3,2-b]furan-3-ol (22 mg, 0.17 mmol, 1.0 eq.), pentamethylacetophenone (35 mg, 0.19 mmol, 1.1 eq.), NaO^tBu (32 mg, 0.34 mmol, 2.0 eq.), $[\text{Cp}^*\text{Ir}(\text{Ts}^*\text{-dpen})(R,R)]$ (13 mg, 0.017 mmol, 10 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO_2 , solid load, Pentane/EtOAc, 95:5 to 90:10) afforded the title compound **18** as a yellow solid (6 mg, 12%). ^1H NMR (400 MHz, CDCl_3) δ 2.02–2.09 (m, 2H, H_6), 2.11 (s, 6H, 2 CH_3), 2.18 (s, 6H, 2 CH_3), 2.23 (s, 3H, CH_3), 2.67–2.87 (m, 2H, H_2 , H_3), 3.11 (dd, $J = 18.3, 6.2$, 1H, H_2), 3.42 (dd, $J = 10.2, 8.0$, 1H, H_2), 3.75 (app td, $J = 8.5, 7.1$, 1H, H_5), 3.85 (ddd, $J = 8.5, 6.8, 4.9$, 1H, H_5), 4.12 (app t, $J = 8.0$, 1H, H_2), 4.63 (app t, $J = 4.3$, 1H, $\text{H}_{3'a}$), 4.74 (app td, $J = 4.3, 2.4$, 1H, $\text{H}_{6'a}$). ^{13}C NMR (101 MHz, CDCl_3) δ 16.1 (2 $\underline{\text{C}}\text{H}_3$), 16.8 ($\underline{\text{C}}\text{H}_3$), 17.3 (2 $\underline{\text{C}}\text{H}_3$), 35.4 (C_6), 40.3 (C_3), 42.6 (C_2), 68.9 (C_5), 72.5 (C_2), 84.0 ($\text{C}_{6'a}$), 84.1 ($\text{C}_{3'a}$), 127.4 (2 C_{qAr}), 133.2 (2 C_{qAr}), 135.6 (C_{qAr}), 140.4 (C_{qAr}), 210.8 (C_1). IR (ATR) ν 650, 820, 836, 882, 936, 1018, 1039, 1093, 1110, 1263, 1305, 1344, 1402, 1447, 1698, 2858, 2934. $[\alpha]_D^{21} = +37.2^\circ$ (c 0.12 CHCl_3). MS (ESI/HRMS) $[\text{M} + \text{Na}]^+$: calcd. for $\text{C}_{19}\text{H}_{26}\text{O}_3\text{Na}$: 325.1774, found 325.1776, $[\text{M} + \text{H}]^+$: calcd. for $\text{C}_{19}\text{H}_{27}\text{O}_3$: 303.1955, found 303.1958.

1-(2,3,4,5,6-Pentamethylphenyl)-2-(3a,5,6,6a-Tetrahydrofuro[3,2-b]furan-3-yl)ethanone (18')



(3R)-Hexahydrofuro[3,2-b]furan-3-ol (22 mg, 0.17 mmol, 1.0 eq.), pentamethylacetophenone (35 mg, 0.19 mmol, 1.1 eq.), NaO^tBu (32 mg, 0.34 mmol, 2.0 eq.), $[\text{Cp}^*\text{Ir}(\text{Ts}^*\text{-dpen})(R,R)]$ (13 mg, 0.017 mmol, 10 mol%) were subjected to **General Procedure**. Purification by flash chromatography (SiO_2 , solid load, pentane/EtOAc, 95:5 to 90:10) afforded the title compound **18'** as a yellow solid (13 mg, 21%). ^1H NMR (400 MHz, CDCl_3) δ 1.95–2.07 (m, 2H, H_6), 2.13 (s, 6H, 2 CH_3), 2.19 (s, 6H, 2 CH_3), 2.23 (s, 3H, CH_3), 3.45 (s, 2H, H_2), 3.44–3.55 (m, 1H, H_5), 3.92 (td, $J = 8.1, 1.1$, 1H, H_5), 5.08 (app t, $J = 6.3$, 1H, $\text{H}_{6'a}$), 5.35 (d, $J = 6.3$, 1H, $\text{H}_{3'a}$), 6.56 (s, 1H, H_2). ^{13}C NMR (101 MHz, CDCl_3) δ 16.1 (2 $\underline{\text{C}}\text{H}_3$), 16.8 ($\underline{\text{C}}\text{H}_3$), 7.4 (2 $\underline{\text{C}}\text{H}_3$), 35.3 (C_6), 40.5 (C_2), 64.2 (C_5), 84.7 ($\text{C}_{6'a}$), 86.5 ($\text{C}_{3'a}$), 105.9 (C_3), 127.6 (2 C_{qAr}), 133.2 (2 C_{qAr}), 135.7 (C_{qAr}), 140.5 (C_{qAr}), 147.7 (C_2), 209.3 (C_1). IR (ATR) ν 586.4, 701.2, 793.7, 1013.6, 1070.5, 1259.6, 1696.5, 2854.8, 2924.2, 2962.8.

$[\alpha]_D^{21} = +9^\circ$ (*c* 0.06 CHCl₃). MS (ESI/BR) [M + H]⁺: calcd. for C₁₉H₂₅O₃: 301.4, found 301.4, [M + Na]⁺: calcd. for C₁₉H₂₄O₃Na: 323.4, found 323.4.

References for the chemical synthesis:

- [1] S. Arita, T. Koike, Y. Kayaki, T. Ikariya, *Organometallics* **2008**, *27*, 2795–2802.
- [2] Y. Zhang, C.-S. Lim, D. S. B. Sim, H.-J. Pan, Y. Zhao, *Angew. Chem. Int. Ed.* **2014**, *53*, 1399–1403.
- [3] D. Abenhaïm, A. Loupy, L. Munnier, R. Tamion, F. Marsais, G. Quéguiner, *Carbohydrate Research* **1994**, *261*, 255–266; A. Loupy, D. A. Monteux, *Tetrahedron* **2002**, *58*, 1541–1549.
- [4] M. Vogler, U. Koert, K. Harms, D. Dorsch, J. Gleitz, P. Raddatz, *Synthesis* **2004**, *2004*, 1211–1228.
- [5] M. Rose, K. Thenert, R. Pfützenreuter, R. Palkovits, *Catal. Sci. Technol.* **2013**, *3*, 938.
- [6] B. J. Stokes, S. M. Opra, M. S. Sigman, *J. Am. Chem. Soc.* **2012**, *134*, 11408–11411.
- [7] A. Stumpf, D. Xu, R. Ranjan, R. Angelaud, F. Gosselin, *Org. Process Res. Dev.* **2023**, *27*, 523–529.


Computational Modelling:

Computational details:

All calculations were performed using the gaussian 09 software (revision D.01).^[1] Electronic energies were computed at the M06 density functional level,^[2] using an ultrafine grid to compute the integrals. This density functional was previously found to give reasonable results on the modelling of Ir-catalyzed reactions.^[3] For geometry optimization the polarized split-valence basis set of Karlsruhe (def2SVP) was used for all atoms except for Ir for which the quasi-relativistic ECP60MWB pseudopotential from Stuttgart-Köln was used in association with its basis set (level I).^[4] Electronic energies were then refined by performing single point calculations (level II) using the polarized triple- ζ basis sets def2TZVP for all atoms. The nature of the extrema was verified by an analytical frequency calculation. Transition states show only one imaginary frequency, and their connectivity were verified by following the intrinsic reaction coordinate (IRC) in both directions. Solvent effect were included both for geometry optimization and single points energy calculations, using the SMD model as defined for toluene.^[5] Gibbs energies and enthalpies were estimated by adding the thermal and entropy corrections computed within the classical harmonic approximation 1 atm and 418K at the level I to the single point electronic energy computed at the level II.


Speciation of [Ir^{III}] complex and substrates:

Since configuration isomerism and epimerization at the asymmetric carbon C* can occur under the reaction conditions (120°C, basic conditions), the speciation of the aldol products has been investigated as well (Scheme S1). Up to 8 configuration isomers can coexist in solution. Ketone E is found to be the most stable one, especially it is more stable than ketone A (namely (Z,S)-A in the main text) by $\Delta G = 1.0$ kcal mol⁻¹. As discussed in next section the conjugate addition at ketones B and C is kinetically less favorable than ketone A (Scheme S3-5).



Scheme S1: Speciation of the aldol condensation product. Energies are given in kcal mol⁻¹.


The speciation of the starting complex has been studied (**Scheme S2**). In the presence of *t*BuONa, the $\text{Ir}^{\text{H,H}}$ complex is deprotonated to give $\text{Ir}^{\text{H,Na}}$. This reaction is exergonic by $\Delta G = -19.1$ kcal mol⁻¹. In the absence of substrate, the most stable intermediate is $\text{Ir}^{\text{H,Na}}$. $\text{Ir}^{\text{H,Na}}$ enables π - π interactions between the phenyl rings of the dpen ligand. As can be seen in structure $\text{Ir}^{\text{H,Na-conf2}}$, removing π - π interactions *via* rotation of the N¹-S or C¹-C² bonds destabilizes the Ir(III)-complex by $\Delta G = 3.5$. As can be seen in structure $\text{Ir}^{\text{H,Na-conf2},\pi\text{-Na}}$, additional Na- π interaction destabilizes more $\text{Ir}^{\text{H,Na-conf2}}$ by 4.4 kcal mol⁻¹.



Scheme S2: Speciation of the [Ir^{III}] complex. Energies are given in kcal mol⁻¹.


Alternative mechanisms:

The mechanisms involving aldol condensation products **A**, **B** and **C** have been studied. Starting from $\text{Ir}^{\text{H,Na}}$ and **A** (**Scheme S3**) the lowest energy barrier is obtained when $\text{Ir}^{\text{H,Na}}$ attacks **A** on the *re* side (**TS-*re*-Ir^{H,Na}-A**, $\Delta G^\ddagger = 29.0$ kcal mol⁻¹) and leads to the experimentally observed +/--(**S,S**)-**17** product. When attacking on the opposite side of **A** (**TS-*si*-Ir^{H,Na}-A**), the free energy is higher by 2.0 kcal mol⁻¹ compared to **TS-*re*-Ir^{H,Na}-A**. Rotation around the N¹-S bond to give **TS-*si*-Ir^{H,Na}-A(conf2)** – in which the sodium atom coordinates to the O² atom from TS-dpen ligand – leads to an even higher energy barrier ($\Delta G^\ddagger = 34.4$ kcal mol⁻¹, compared to $\text{Ir}^{\text{H,Na}}$ and **A**).




Scheme S3: Free energy profile computed for the formation of (S,S) -17 using aldol condensation product **A**. ΔG (ΔH) in kcal mol⁻¹.

The kinetic for the formation of the experimentally obtained product +/- (R,R) -17 is very similar for the conjugated ketone **B** (Scheme S4). Indeed, the lowest energy barrier leading to (R,R) -17 via $TS-Ir^{H,Na}-B^{MeONa}$ is about 34.8 kcal mol⁻¹ (i.e. 5.8 kcal mol⁻¹ higher in energy than in the case of ketone **A**). Decoordination of the O³ atom from the methoxy group to the sodium counter-ion has a detrimental effect on the kinetic of the reaction ($TS-Ir^{H,Na}-B$, $\Delta G^\ddagger = 35.6$ kcal mol⁻¹). Adding new π - π interactions between the phenyl groups of the Ts-dpen ligand through rotation of the N¹-S bond was found detrimental (structure $TS-Ir^{H,Na}-B^{MeO-Na-conf2}$, $\Delta G^\ddagger = 37.1$ kcal mol⁻¹ starting from $Ir^{H,Na}$ and **B**).



Scheme S4: Free energy profile computed for the formation of (R,R) -17 using aldol condensation product **B**. Energies are given in kcal mol⁻¹.

The mechanism starting from conjugated ketone **C** and leading to the experimentally observed product +/- **(R,R)-17** is depicted in **figure S3**. The adduct formation is thermodynamically unfavorable ($\Delta G = 10.8 \text{ kcal mol}^{-1}$, starting from separated molecules $\text{Ir}^{\text{H,Na}}$ and **C**). The energy barrier to reach $\text{TS-Ir}^{\text{H,Na-C}}$ is about $\Delta G^\ddagger = 30.9 \text{ kcal mol}^{-1}$. This energy barrier is higher to that of $\text{TS-re-(Z,S)-A-Ir}^{\text{H,Na}}$ by 1.9 kcal




mol^{-1} .

Scheme S5: Free energy profile computed for the formation of **(R,R)-17** using aldol condensation product **C**. ΔG (ΔH) in kcal mol^{-1} .


Interaction-distortion analyses:

The interaction-distortion analysis (IDA) was used to explain the selectivity of the hydride transfer (**Scheme S6**). For this purpose, we decomposed each transition state ($\text{TS-re-(Z,S)-A-Ir}^{\text{H,Na}}$ and $\text{TS-si-(Z,S)-A-Ir}^{\text{H,Na}}$) into two fragments and used **A** and $\text{Ir}^{\text{H,Na}}$ as a reference. When attacking at the *re* face ($\text{TS-re-(Z,S)-A-Ir}^{\text{H,Na}}$, **Scheme S5-a**), both the conjugated ketone **A** and the catalyst $\text{Ir}^{\text{H,Na}}$ are distorted to the same extent ($\Delta E_{\text{dist}}(\text{Ir}^{\text{H,Na}}) = 15.4$, ($\Delta E_{\text{dist}}(\text{A}) = 15.3 \text{ kcal mol}^{-1}$, compared to separated **A** and $\text{Ir}^{\text{H,Na}}$). The TS is stabilized by $\Delta E_{\text{int}} = -24.1 \text{ kcal mol}^{-1}$ in the transition state, and therefore the overall difference in electronic energy is $\Delta E = +6.5 \text{ kcal mol}^{-1}$. This transition state leads to the product **(S,S)-17**, which is the one experimentally observed. Interestingly, when attacking at the *si* face ($\text{TS-si-(Z,S)-A-Ir}^{\text{H,Na}}$, **Scheme S5-b**), the substrate is considerably more distorted ($\Delta E_{\text{dist}}(\text{A}) = 20.1 \text{ kcal mol}^{-1}$). The interaction contribution to the difference in electronic energy is also more important ($\Delta E_{\text{int}} = -28.4 \text{ kcal mol}^{-1}$; $\Delta E = 6.0 \text{ kcal mol}^{-1}$ compared to **A** and $\text{Ir}^{\text{H,Na}}$) and fully compensates the distortion contribution. This transition state leads to the product **(R,S)-17**, which was not experimentally observed. Results of the Interaction-distortion analysis correlates with the geometries of the transition states presented in **Table S1**. It appears that distortion of the substrate and Ir-H bonds in the transition state are determinant parameters for the selectivity of the reaction. The most favorable transition state is the earliest one, *i.e.* where the substrate shows minimal distortion and the shortest Ir-H bond. It corresponds to $\text{TS-re-(Z,S)-A-Ir}^{\text{H,Na}}$.



Scheme S6: Interaction – Distortion analyses for $TS\text{-}re\text{-}(Z,S)\text{-}A\text{-}Ir^{H,Na}$ and $TS\text{-}si\text{-}(Z,S)\text{-}A\text{-}Ir^{H,Na}$. All electronic energies (ΔE) are given in kcal mol⁻¹.

Table S1: Sum of the C²-C¹-C³, C³-C¹-C⁴ and C⁴-C¹-C² angles, percentage of lengthening of the Ir-H bond in the TS compared to the pre-TS adduct and Gibbs free energies relative to $Ir^{H,Na}$ and A. Angles are given in °, energies in kcal mol⁻¹.

	<i>re</i> -(Z,S)-A-Ir ^{H,Na}	<i>si</i> -(Z,S)-A-Ir ^{H,Na}	TS- <i>re</i> -(Z,S)-A-Ir ^{H,Na}	TS- <i>si</i> -(Z,S)-A-Ir ^{H,Na}	
Angles sum	358	359	345	332°	
Ir-H bond lengthening	0.0	0.0	110%	115%	
ΔG	7.9	5.7	29.0	31.0	
	Adducts		Transition states		

Cartesian coordinates:

The cartesian coordinates for all discussed structures are available in additional XYZ file.

References for the computational study:


- [1] a) R. D. Gaussian 09, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, Gaussian, Inc., Wallingford CT, 2013., *Gaussian, Inc., Wallingford CT* **2013**; b) J. K. B. NBO 6.0. E. D. Glendening, A. E. Reed, J. E. Carpenter, J. A. Bohmann, C. M. Morales, C. R. Landis, and F.

- Weinhold (Theoretical Chemistry Institute, University of Wisconsin, Madison, WI, 2013); <http://nbo6.chem.wisc.edu/>.
- [2] Y. Zhao, D. G. Truhlar, The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals *Theoretical Chemistry Accounts* 2008, **120**, 215.
- [3] a) K. H. Hopmann, How Accurate is DFT for Iridium-Mediated Chemistry? *Organometallics* 2016, **35**, 3795; b) K. A. Moltved, K. P. Kepp, The Metal Hydride Problem of Computational Chemistry: Origins and Consequences, *J. Phys. Chem. A* 2019, **123**, 2888.
- [4] a) D. Andrae, U. Häussermann, M. Dolg, H. Stoll, H. Preuss, Energy-adjusted *ab initio* pseudopotentials for the second and third row transition elements *Theoretica Chimica Acta* **1990**, *77*, 123 ; b) F. Weigend, R. Ahlrichs, Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy, *Phys. Chem. Chem. Phys.* 2005, **7**, 3297.
- [5] A. V. Marenich, C. J. Cramer, D. G. Truhlar, Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions, *J. Phys. Chem. B* **2009**, *113*, 6378.


Spectral data:

^1H NMR spectrum of $[\text{Cp}^*\text{-Ir-NTr} \cdot \text{HCl}]$ (Ir-1) (300 MHz, CDCl_3)

JFR629.1.fid -- 1H zg90 -- 1H_8




^1H NMR spectrum of *N*-((*1R,2R*)-2-amino-1,2-diphenylethyl)-2,3,4,5,6-





pentamethylbenzenesulfonamide (300 MHz, CDCl_3)

^1H NMR spectrum of [$\text{Cp}^*\text{Ir}(\text{Ts}^*\text{-dpen})(R,R)$] (*Ir-2*) (300 MHz, CDCl_3)




¹H NMR spectrum of (3*R*,6*S*)-6-(benzyloxy)hexahydrofuro[3,2-*b*]furan-3-ol (1) (300 MHz, CDCl₃)

JFR069-dry.100.fid — no_title





¹³C NMR spectrum of (3*R*,6*S*)-6-(benzyloxy)hexahydrofuro[3,2-*b*]furan-3-ol (1) (101 MHz, CDCl₃)

JFR069-dry.102.fid — no_title — 13C_CPD_128 CDCl₃ /opt/topspin lco_insa 32




¹H NMR spectrum of (3*R*,6*R*)-6-((*tert*-butyldimethylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-ol (6) (400 MHz, CDCl₃)

AC17.1 — AC17.1 Lco-insa 24mg CDCl₃ — H1.ab CDCl₃ /opt/topspin lco_insa 22 —




¹³C NMR spectrum of (3*R*,6*R*)-6-((*tert*-butyldimethylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-ol (6) (101 MHz, CDCl₃)

AC17.1 — AC17.1 Lco-insa 24mg CDCl₃ — C13-CPD.ab CDCl₃ /opt/topspin lco_insa 22 —




¹H NMR spectrum of (3*R*,6*S*)-6-hydroxyhexahydrofuro[3,2-*b*]furan-3-yl acetate (400 MHz, CDCl₃)


JFR027-1.100.fid — AcOIS




¹³C NMR spectrum of (3*R*,6*S*)-6-hydroxyhexahydrofuro[3,2-*b*]furan-3-yl acetate (101 MHz, CDCl₃)




¹H NMR spectrum of (3R,6S)-6-((*tert*-butyldiphenylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-yl acetate (400 MHz, CDCl₃)




¹³C NMR spectrum of (3R,6S)-6-((*tert*-butyldiphenylsilyl)oxy)hexahydrofuro[3,2-*b*]furan-3-yl acetate (101 MHz, CDCl₃)



¹H NMR spectrum of (3R,6S)-6-Methoxyhexahydrofuro[3,2-b]furan-3-yl acetate (400 MHz, CDCl₃)




¹³C NMR spectrum of (3R,6S)-6-Methoxyhexahydrofuro[3,2-b]furan-3-yl acetate (101 MHz, CDCl₃)




¹H NMR spectrum of (3*R*,6*S*)-6-methoxyhexahydrofuro[3,2-*b*]furan-3-ol (8) (400 MHz, CDCl₃)

JFR039F.1.fid — H1.ab CDCl₃ /opt/topspin lco_insa 25




¹³C NMR spectrum of (3*R*,6*S*)-6-methoxyhexahydrofuro[3,2-*b*]furan-3-ol (8) (101 MHz, CDCl₃)

JFR039F.2.fid — C13-CPD.ab CDCl₃ /opt/topspin lco_insa 25




¹H NMR spectrum of (3*R*,6*S*)-6-(*tert*-butoxy)hexahydrofuro[3,2-*b*]furan-3-ol (9) (400 MHz, CDCl₃)

JFR041-1.100.fid
IS(OtBu)




¹³C NMR spectrum of (3*R*,6*S*)-6-(*tert*-butoxy)hexahydrofuro[3,2-*b*]furan-3-ol (9) (101 MHz, CDCl₃)

JFR041-1.102.fid
no_title
13C_CPD_128 CDCl3 /opt/topspin lco_insa 54




¹H NMR spectrum of 5-methyltetrahydrofuran-3-ol (400 MHz, CDCl₃)

JFR151-2_CDCI3.105.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 34




¹³C NMR spectrum of (3R,4S)-4-methyltetrahydrofuran-3-ol (101 MHz, CDCl₃)

JFR151-2_CDCI3.107.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 34




¹H NMR spectrum of (3*R*,4*S*)-4-methyltetrahydrofuran-3-ol (±) (400 MHz, CDCl₃)

JFR210D.100.fid — no_title





¹³C NMR spectrum of (3*R*,4*S*)-4-methyltetrahydrofuran-3-ol (±) (101 MHz, CDCl₃)

JFR210D.101.fid — no_title




¹H NMR spectrum of (3*R*,4*S*)-4-propyltetrahydrofuran-3-ol (±) (300 MHz, CDCl₃)

JFR471F.100.fid — no_title




¹³C NMR spectrum of (3*R*,4*S*)-4-propyltetrahydrofuran-3-ol (±) (75 MHz, CDCl₃)


JFR471F.102.fid — no_title



¹H NMR spectrum of (3*S*,4*S*)-4-methoxytetrahydrofuran-3-ol (±) (400 MHz, CDCl₃)




¹³C NMR spectrum of (3*S*,4*S*)-4-methoxytetrahydrofuran-3-ol (±) (101 MHz, CDCl₃)




¹H NMR spectrum of (3R)-hexahydrofuro[3,2-b]furan-3-ol (300 MHz, CDCl₃)

JFR423-3.100.fid — no_title




¹³C NMR spectrum of (3R)-hexahydrofuro[3,2-b]furan-3-ol (75 MHz, CDCl₃)

JFR423-3.101.fid — no_title




¹H NMR spectrum of 2-((3*R*,6*S*)-6-(benzyloxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) (400 MHz, CDCl₃)

JFR074-3-1F.100.fid — no_title



¹³C NMR spectrum of 2-((3*R*,6*S*)-6-(benzyloxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) (101 MHz, CDCl₃)


JFR074-3-1C.13.100.fid — no_title — 13C_CPD_1k CDCl₃ /opt/topepin lco_insa 15




2-((3*R*,6*S*)-6-(Benzyloxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (2) – S73

Determination of the absolute configuration of 2 by NOESY

JFR074-3-1F.105.ser — no_title — 1H_noesy_8 CDCl3 /opt/topspin lco_insa 15




JFR074-3-1F.105.ser — no_title — 1H_noesy_8 CDCl3 /opt/topspin lco_insa 15




¹H NMR spectrum of 2-((3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (10) (400 MHz, CDCl₃)

JFR671-2F.100.fid — no_title




¹³C NMR spectrum of 2-((3*R*,6*S*)-6-Methoxyhexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (10) (101 MHz, CDCl₃)

JFR671-2F.101.fid — no_title




¹H NMR spectrum of 2-((3*R*,6*S*)-6-(*tert*-butoxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12) (400 MHz, CDCl₃)




¹³C NMR spectrum of 2-((3*R*,6*S*)-6-(*tert*-butoxy)hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (12) (101 MHz, CDCl₃)

JFR057-4_102.fid — no_title — 13C_CPD_128 CDCl3 /opt/topspin lco_insa 56




¹H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13) (400 MHz, CDCl₃)

JFR61-2.100.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 59




¹³C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone (13) (101 MHz, CDCl₃)

JFR061-2C.100.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 39




¹H NMR spectrum of 2-(5-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (14) (400 MHz, CDCl₃)

JFR161-3F.100.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 58




¹³C NMR spectrum of 2-(5-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (14) (101 MHz, CDCl₃)

JFR161-3F.102.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 58




¹H NMR spectrum of 2-(4-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (15) (400 MHz, CDCl₃)

JFR214-2F.100.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 52




¹³C NMR spectrum of 2-(4-methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 15 (101 MHz, CDCl₃)


JFR214-2F.102.fid



¹H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethanone (16) (400 MHz, CDCl₃)




¹³C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethanone (16) (101 MHz, CDCl₃)




¹H NMR spectrum of 2-((3*R*,4*R*)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17) (400 MHz, CDCl₃)

JFR225-2F.100.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 49




JFR225-2F.103.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 49




¹³C NMR spectrum of 2-((3*R*,4*R*)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (17) (101 MHz, CDCl₃)

¹H NMR spectrum of 2-((3*R*)-hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18) (400 MHz, CDCl₃)




¹³C NMR spectrum of 2-((3*R*)-hexahydrofuro[3,2-*b*]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone (18) (101 MHz, CDCl₃)

JFR141-3F.102.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 43



¹H NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(3a,5,6,6a-Tetrahydrofuro[3,2-*b*]furan-3-yl)ethanone (18²) (400 MHz, CDCl₃)

JFR141-2F.100.fid — no_title — 1H_8 CDCl3 /opt/topspin lco_insa 42



¹³C NMR spectrum of 1-(2,3,4,5,6-pentamethylphenyl)-2-(3a,5,6,6a-Tetrahydrofuro[3,2-*b*]furan-3-yl)ethanone (18²) (101 MHz, CDCl₃)

JFR141-2F.102.fid — no_title — 13C_CPD_1k CDCl3 /opt/topspin lco_insa 42

